Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)

DOI Web Site 1 Citations

Randall Severance

Synexus Clinical Research, Chandler, AZ, USA
Howard Schwartz

Research Centers of America, Hollywood, FL, USA
Ron Dagan

Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel
Laurie Connor

Merck & Co., Inc., Kenilworth, NJ, USA
Jianing Li

Merck & Co., Inc., Kenilworth, NJ, USA
Alison Pedley

Merck & Co., Inc., Kenilworth, NJ, USA
Jonathan Hartzel

Merck & Co., Inc., Kenilworth, NJ, USA
Tina M. Sterling

Merck & Co., Inc., Kenilworth, NJ, USA
Katrina M. Nolan

Merck & Co., Inc., Kenilworth, NJ, USA
Gretchen M. Tamms

Merck & Co., Inc., Kenilworth, NJ, USA
Luwy K. Musey

Merck & Co., Inc., Kenilworth, NJ, USA
Ulrike K. Buchwald

Merck & Co., Inc., Kenilworth, NJ, USA

Journal

Human Vaccines & Immunotherapeutics

Human Vaccines & Immunotherapeutics 18 (1), 1-14, 2021-11-02

Informa UK Limited

Back to top